Organon Canada Wins Approval for NDUVRA 1% Steroid-Free Cream for Atopic Dermatitis

Organon Canada, a subsidiary of Organon & Co. (OGN), said it received Canadian approval for NDUVRA (tapinarof) cream, 1%, a steroid-free topical treatment for moderate to severe atopic dermatitis in adults and children aged 2 and older. The approval follows Tapinarof cream's initial Canadian clearance earlier in 2025 for plaque psoriasis in adults. NDUVRA is a topical aryl hydrocarbon receptor agonist. Atopic dermatitis affects up to 20% of children and 3% of adults globally, and roughly 15% of children and 4% of adults in Canada. Organon shares closed at $13.73 on the NYSE, up 0.07%.